Newborn screening for rare genetic diseases gets a faster path to market

US health regulators have created a new, faster approval process for tests that screen newborns for lysosomal storage disorders. This means more of these tests can reach hospitals and parents sooner, making early detection of these rare conditions more common.

For years, new medical tests, even for rare diseases, faced a slow and expensive approval process. This change means that a specific type of newborn screening test can now be classified more quickly, reducing the cost and time it takes to get them to market. This could lead to more widespread screening for these conditions, which often benefit greatly from early treatment.